Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 4
2004 8
2005 5
2006 5
2007 8
2008 5
2009 5
2010 4
2011 5
2012 2
2013 6
2014 3
2015 7
2016 6
2017 13
2018 13
2019 13
2020 18
2021 16
2022 10
2023 6
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, Offidani M, Zamagni E, Ledda A, Grasso M, Ballanti S, Spadano A, Cea M, Patriarca F, D'Agostino M, Capra A, Giuliani N, de Fabritiis P, Aquino S, Palmas A, Gamberi B, Zambello R, Petrucci MT, Corradini P, Cavo M, Boccadoro M. Gay F, et al. Among authors: giuliani n. Lancet Oncol. 2021 Dec;22(12):1705-1720. doi: 10.1016/S1470-2045(21)00535-0. Epub 2021 Nov 11. Lancet Oncol. 2021. PMID: 34774221 Free article. Clinical Trial.
Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy.
Ganan-Gomez I, Yang H, Ma F, Montalban-Bravo G, Thongon N, Marchica V, Richard-Carpentier G, Chien K, Manyam G, Wang F, Alfonso A, Chen S, Class C, Kanagal-Shamanna R, Ingram JP, Ogoti Y, Rose A, Loghavi S, Lockyer P, Cambo B, Muftuoglu M, Schneider S, Adema V, McLellan M, Garza J, Marchesini M, Giuliani N, Pellegrini M, Wang J, Walker J, Li Z, Takahashi K, Leverson JD, Bueso-Ramos C, Andreeff M, Clise-Dwyer K, Garcia-Manero G, Colla S. Ganan-Gomez I, et al. Among authors: giuliani n. Nat Med. 2022 Mar;28(3):557-567. doi: 10.1038/s41591-022-01696-4. Epub 2022 Mar 3. Nat Med. 2022. PMID: 35241842 Free PMC article.
Editorial: Immunotherapy in Multiple Myeloma.
Giuliani N, Malavasi F. Giuliani N, et al. Front Immunol. 2019 Aug 14;10:1945. doi: 10.3389/fimmu.2019.01945. eCollection 2019. Front Immunol. 2019. PMID: 31475006 Free PMC article. No abstract available.
Postmortem Imaging: An Update.
Cafarelli FP, Grilli G, Zizzo G, Bertozzi G, Giuliani N, Mahakkanukrauh P, Pinto A, Guglielmi G. Cafarelli FP, et al. Among authors: giuliani n. Semin Ultrasound CT MR. 2019 Feb;40(1):86-93. doi: 10.1053/j.sult.2018.10.012. Epub 2018 Oct 28. Semin Ultrasound CT MR. 2019. PMID: 30686372 Review.
Possible targets to treat myeloma-related osteoclastogenesis.
Bolzoni M, Toscani D, Storti P, Marchica V, Costa F, Giuliani N. Bolzoni M, et al. Among authors: giuliani n. Expert Rev Hematol. 2018 Apr;11(4):325-336. doi: 10.1080/17474086.2018.1447921. Epub 2018 Mar 9. Expert Rev Hematol. 2018. PMID: 29495905 Review.
Role of Galectins in Multiple Myeloma.
Storti P, Marchica V, Giuliani N. Storti P, et al. Among authors: giuliani n. Int J Mol Sci. 2017 Dec 17;18(12):2740. doi: 10.3390/ijms18122740. Int J Mol Sci. 2017. PMID: 29258207 Free PMC article. Review.
The Proteasome and Myeloma-Associated Bone Disease.
Accardi F, Toscani D, Costa F, Aversa F, Giuliani N. Accardi F, et al. Among authors: giuliani n. Calcif Tissue Int. 2018 Feb;102(2):210-226. doi: 10.1007/s00223-017-0349-1. Epub 2017 Oct 28. Calcif Tissue Int. 2018. PMID: 29080972 Review.
Oncolytic Virotherapy and Microenvironment in Multiple Myeloma.
Marchica V, Costa F, Donofrio G, Giuliani N. Marchica V, et al. Among authors: giuliani n. Int J Mol Sci. 2021 Feb 24;22(5):2259. doi: 10.3390/ijms22052259. Int J Mol Sci. 2021. PMID: 33668361 Free PMC article. Review.
CD38 and bone marrow microenvironment.
Chillemi A, Zaccarello G, Quarona V, Lazzaretti M, Martella E, Giuliani N, Ferracini R, Pistoia V, Horenstein AL, Malavasi F. Chillemi A, et al. Among authors: giuliani n. Front Biosci (Landmark Ed). 2014 Jan 1;19(1):152-62. doi: 10.2741/4201. Front Biosci (Landmark Ed). 2014. PMID: 24389178 Free article. Review.
Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R, Musto P, Rota-Scalabrini D, Paris L, Gamberi B, Palmas A, Aquino S, de Fabritiis P, Giuliani N, De Rosa L, Gozzetti A, Cellini C, Bertamini L, Capra A, Oddolo D, Vincelli ID, Ronconi S, Pavone V, Pescosta N, Cea M, Fioritoni F, Ballanti S, Grasso M, Zamagni E, Belotti A, Boccadoro M, Gay F. Mina R, et al. Among authors: giuliani n. Lancet Oncol. 2023 Jan;24(1):64-76. doi: 10.1016/S1470-2045(22)00693-3. Epub 2022 Dec 14. Lancet Oncol. 2023. PMID: 36528035 Clinical Trial.
143 results